Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

24 April 2018

Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018

24 April 2018

Cerbios-Pharma SA – Enterococcus faecium SF68®: a model for efficacy and safety for Pharmaceutical Probiotics

20 April 2018

Cerbios’ Senior Scientist on Antibody Drug Conjugates

6 April 2018

APR Applied Pharma Research – PKU Management: insights from a global market research by APR

5 April 2018

Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU)

28 February 2018

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

30 January 2018

US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid

18 January 2018

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

12 January 2018

A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award

9 January 2018